Acquired resistance to cetuximab (CTX), a monoclonal antibody that can block the binding of EGF to EGFR and inhibit the activation of downstream pathways AKT and ERK1/2, was found in head and neck squamous cell carcinomas (HNSCC) [105, 106]. Here, AKT1 is linked to head and neck squamous cell carcinoma.